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Do symbiotic and Vitamin E supplementation 
have favorite effects in nonalcoholic fatty 
liver disease? A randomized, double‑blind, 
placebo‑controlled trial
Golnaz Ekhlasi, Roya Kolahdouz Mohammadi, Shahram Agah, Mitra Zarrati, Agha Fatemeh Hosseini,  
Seyed Soroush Soltani Arabshahi, Farzad Shidfar
Iran National Science Foundation, School of Health, Iran University of Medical Sciences, Tehran, Iran
and considered the hepatic manifestation of metabolic 
syndrome or insulin resistance (IR) and expanding in line 
with outbreak of obesity and type 2 diabetes.[3,4]
In spite of tremendous research, the mechanisms 
underlying NAFLD development remain to be 
clarified.[5] However, IR, visceral adiposity, adipokines, 
oxidative stress, and increased free fatty acid (FFA) 
release contribute to the pathogenesis of liver steatosis.
[6] Recently, increased intestinal permeability and 
alteration in the ratio of gut microbiota have been seen in 
patients with obesity and NAFLD, attributing a potential 
role in the pathogenesis of NAFLD.[7]
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) comprises 
a spectrum of liver disorders, ranging from fatty liver 
alone to steatohepatitis, steatonecrosis, and nonalcoholic 
steatohepatitis (NASH).[1] NAFLD patients with simple 
steatosis are unlikely to progress to cirrhosis whereas 20% 
of patients with NASH are at the greatest risk of progressing 
to cirrhosis over 15 years as a result of inflammation 
and hepatocellular injury.[2] NAFLD is increasingly 
recognized as a serious, worldwide public health concern 
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Intestinal microflora has been first claimed to have a positive 
influence on human health, and the ensuing research has 
by now soundly confirmed this concept. Probiotics are 
live microorganisms that, when consumed in adequate 
quantities, confer a health benefit to the host.[8] In the 
past two decades, a number of investigators have sought 
to determine that probiotics along with prebiotics have 
anti‑inflammatory, immunomodulatory, antifibrotic, and 
lipid‑lowering properties. Besides, regarding fibrotic and 
steatotic characteristics of NAFLD,[9,10] it was assumed that 
symbiotic supplementation might act as a novel therapeutic 
strategy in patients with this disease.
Cytotoxic FFA oxidation in liver can upregulate cytokines 
production, which, in turn, induces cytochrome P450 
enzyme expression and reduces liver concentration of 
antioxidants.[11] Furthermore, increased production of 
cytokines in hepatic stellate cells (HSCs) leads to fibrogenesis 
and extracellular matrix protein deposition.[12] Vitamin E as 
a fat‑soluble vitamin with antioxidant properties can inhibit 
proinflammatory cytokine production and attenuate hepatic 
fibrosis production.[13]
Research on the NAFLD and probiotic supplementation 
has been mostly restricted to a limited number of some 
species of probiotics. In addition, far too little attention 
has been paid to synergistic effect of multiple strains 
of probiotic and Vitamin E supplements in NAFLD 
patients. The present study was, therefore, performed to 
investigate the synergistic effect of symbiotic and Vitamin E 
supplementation on some indicators such as liver enzymes, 
leptin, lipid profile, and glycemic status in NAFLD patients.
MATERIALS AND METHODS
Recruitment and eligibility screening
The present randomized, double‑blind controlled clinical trial 
was conducted in Tehran, Iran, during 2012–2013 among sixty 
NAFLD patients (48 men and 12 women) aged 25–64 years, 
who were recruited from Hazrat‑e‑Rasoul Medical 
Complex (Colorectal Research Center) in Tehran, Iran, which 
is only devoted to gastrointestinal (GI) and liver disorders. In 
this double‑blind, placebo‑controlled trial, eligible patients 
signed a written consent form after a full review of the 
risks and benefits of the study, which was approved by the 
Ethical Committee of Iran University of Medical Sciences 
(grant number: 90005246) in 2011 and registered at the 
Iranian Registry of Clinical Trials (IRCT201111082709N22) 
and was funded by the Iran National Science Foundation. 
All procedures were in accordance with the guidelines in 
the Helsinki declaration (2013).
The diagnosis of NAFLD was based on hepatic 
ultrasonography (Grade 1–3), associated with persistently 
elevated levels of alanine aminotransferase (ALT) 
concentration (30 mg/dL) for 6 months before the study and 
at the time of randomization. The eligibility criteria included 
females and males between the ages of 25 and 64 years with 
body mass index (BMI) ranging from 25 to 35 kg/m2.
Exclusion criteria comprised any of the pathologic conditions 
affecting liver such as viral hepatitis, alcohol consumption, 
hypothyroidism, Wilson disease, acute systemic disease, 
cystic fibrosis, coeliac disease, and alpha‑1‑antitrypsin 
deficiency. Patients were also excluded if they had history 
of cancer, metabolic disorders, cardiovascular (CVD), and 
autoimmune diseases as well as drug or alcohol abuse. 
Diabetes mellitus, pregnancy, lactation, menstruation at 
the time of blood sampling, infectious diseases during 
the study, use of nonsteroidal anti‑inflammatory drugs, 
antibiotics, and probiotics and food supplements preceding 
enrolment were also considered exclusion criteria.
Study design and randomization
All eligible patients with NAFLD were recruited during 
2012–2013 [Figure 1]. Each symbiotic capsule (Protexin; 
Probiotics International Ltd., Lopen Head, Somerset, 
United Kingdom) contained Lactobacillus casei, Lactobacillus 
rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, 
Lactobacillus acidophilus, Bifidobacterium longum, Lactobacillus 
bulgaricus, and prebiotic (fructooligosaccharide) and 
probiotic cultures (magnesium stearate [source: Mineral 
and vegetable] and a vegetable capsule (hydroxypropyl 
methylcellulose)). The concentration of each probiotic strain 
was 2 × 108 CFU/g per capsule. Symbiotic supplements 
were administered as two capsules per day orally after 
the main meal. Two identical‑appearing placebo capsules 
(corn starch, Zahravi Pharmaceutical Co.,) were taken daily 
by participants assigned to either placebo or Vitamin E 
group. The justification for choosing this dosage was based 
on the earlier study.[14]
Vitamin E (RRR‑α‑tocopherol, Zahravi Pharmaceutical Co.,) 
at a daily dosage of 400 IU and similar‑appearing placebo 
was administered orally. This chosen Vitamin E dose was 
similar to previous study in NAFLD patients.[15]
Randomization was carried out according to balanced block 
randomization procedure; participants, nutrition specialists, 
and outcome assessors were all blinded to the interventions 
into which the individuals were allocated.
Our patients were randomly assigned in the symbiotic 
and Vitamin E trial: 15 were assigned to receive symbiotic 
and Vitamin E‑like placebo capsule (group Sym), 15 were 
assigned to receive Vitamin E and symbiotic‑like placebo 
(group Vitamin E), 15 were assigned to symbiotic and 
Vitamin E supplementation (group Sym + Vitamin E), and 
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15 were given symbiotic‑like placebo and Vitamin E‑like 
placebo supplementation (control).
At the beginning of the study, physical examinations, 
medical history, diet, and physical activity level of each 
patient were assessed. The patients were asked not to 
consume any probiotic containing food, yogurt, or its 
products during an initial 2 weeks run‑in period before 
the dietary intervention. At the end of the run‑in period, 
eligible patients were randomly assigned to one of the 
named groups. They were also asked not to consume other 
probiotic products during the intervention.
Compliance was monitored by phone calls weekly and 
verified using capsule counts (number of capsules left in 
the capsule bottle at the end of the study).
Clinical, paraclinical, and dietary intake assessments
The patients underwent anthropometric and laboratory 
assessments at the baseline and at the end of the study. 
Weight, height, and waist circumferences of each 
patient were measured according to the standard 
protocols. Each individual’s BMI was calculated as body 
weight (kg)/height2 (m).
Blood samples were obtained and analyzed after 10–12 h 
of overnight fasting. All blood analyses were done at 
the same laboratory using standard laboratory methods. 
ALT, aspartate aminotransferase (AST), and alkaline 
phosphatase (ALP) concentrations were measured by 
enzymatic methods (Pars Azmoon Inc, Tehran, Iran). Leptin 
serum concentrations were measured using a commercial 
ELISA kit (LDN, Nordhorn, Germany).
Figure 1: Flow diagram of patient recruitment and randomization process
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Total cholesterol (TC) and serum triglycerides (TG) 
were tested using the enzymatic colorimetric method. 
High‑density lipoprotein cholesterol (HDL‑C) measurement 
was done after precipitation of the apolipoprotein B‑100 
(apo B‑100) containing lipoproteins with phosphotungstic 
acid. All of these analyses were performed using commercial 
kits (Pars Azmoon Co., Iran). Low‑density lipoprotein 
cholesterol (LDL‑C) concentrations were calculated using the 
Friedewald equation: LDL‑C = TC‑HDL‑C‑TG/5.[16] Serum 
apolipoprotein A‑1 (apo A‑1) and apo B‑100 concentrations 
were determined by immunoturbidimetric methods using 
commercial kits (Roche Diagnostics, Mannheim, Germany).
Serum glucose concentrations were measured using the 
enzymatic colorimetric method with glucose oxidase 
(Pars Azmoon Co., Iran). Fasting insulin concentrations were 
analyzed by ELISA kit (DiaMetra Co., Italy). Homeostasis 
model assessment for IR (HOMA‑IR) as a marker of IR was 
calculated by the following formula: [17] HOMA‑IR = (fasting 
insulin [mU/L] × fasting blood glucose (mg/dL))/405.
For the assessment of nutrient intakes, patients were asked 
to complete the 24 h food recall questionnaire, including 
2 week days and 1 weekend at the baseline and at the end 
of the 1st and 2nd month after the intervention. Dietary 
intakes were then analyzed using Nutritionist IV software 
(First Databank Inc., Hearst Corp., San Bruno, CA, USA). 
The nutrient database of Nutritionist IV software was based 
on the United States Department of Agriculture and data 
related to this software were modified for Iranian foods. 
Physical activity was determined with the short form of the 
International Physical Activity Questionnaire.[18]
Statistical analysis
Data analysis was performed using SPSS software 
(SPSS Inc., Version 20, Chicago, IL, USA) and presented 
as mean ± standard deviation. The data were analyzed 
according to the intention‑to‑treat principle.
Normal distribution of data was assured using 
Kolmogorov–Smirnov test. Differences between groups 
were determined by one‑way analysis of variance or 
Kruskal–Wallis for continuous data, and the Chi‑square 
test for categorical data. Post hoc comparisons were carried 
out with Tukey’s test. The within‑group comparisons of 
data were performed using paired t‑test and Wilcoxon test 
when appropriate. The results were considered statistically 
significant if P < 0.05.
RESULTS
Characteristics of the patients
Among 65 patients enrolled in the study, sixty of the patients 
completed 8 weeks of treatment and had end‑of‑study 
clinical and laboratory data. In other words, five of the 
participants were excluded from the statistical analysis 
because of pregnancy, traveling, and heart attack.
In this study, 48 men and 12 women, aged 25–64 years, 
completed the study and there were no significant 
differences among intervention groups in terms of 
weight, BMI, and waist circumference at study baseline. 
Furthermore, we found no significant differences in the 
weight, BMI, and waist circumference within and between 
all treatment groups after the intervention [Table 1].
Serum liver enzymes and leptin
A significant improvement in several measured variables in 
this study was seen within and between all study groups. 
There was a significant decrease in mean serum ALT levels 
in patients of group Sym and Sym + Vitamin E  [Table 2]. 
However, the mean reduction in the Sym + Vitamin E group 
was greater than the control group (P < 0.001). No significant 
reduction in serum ALT levels was found in Vitamin E 
group compared to the control.
The differences in serum AST levels are shown in Table 2. 
The changes for serum AST were significant in all three 
groups versus control while they were more evident for 
Sym + Vitamin E group [Table 2]. Serum ALP concentrations 
significantly decreased in all groups except the control 
although these reductions in the Sym + Vitamin E group 
were greater in comparison to the control group [Table 2].
A significant reduction in the concentrations of serum leptin 
was observed in Sym and Sym + Vitamin E groups after 
the 8‑week of intervention. The reduction in serum leptin 
levels of the Sym + Vitamin E group compared with the 
control was − 11.4 ± 2.76 compared with 2.54 ± 3.02 ng/mL 
(P < 0.001) [Table 2].
Lipid profile
The range of measured lipid profiles [Table 3] was not 
statistically different among all of the four groups at the 
beginning of the intervention though the amounts of several 
of them were significantly affected after the 8‑week dietary 
intervention. As shown in Table 3, a significant reduction in 
TG and TC was observed only in Sym and Sym + Vitamin E 
groups and the P < 0.001 for TG and TC in both groups. 
LDL‑C levels decreased significantly in all three groups 
except the control after the intervention. Moreover, the 
intake of symbiotic plus Vitamin E supplements led to 
a more significant decrease in LDL‑C compared with 
control (−22 ± 10.63 vs. 1.43 ± 2.67 mg/dL, P < 0.001).
Just for TG and TC serum concentrations, we observed 
statistically significant differences between the groups after the 
8‑week dietary intervention (P = 0.004 and 0.001, respectively). 
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In other words, compared with the control group, patients 
taking symbiotic plus Vitamin E had a significant decrease 
in TC (P = 0.002) and TG serum levels (P = 0.047). In contrast, 
serum concentrations of HDL‑C had no significant changes 
Table 1: Anthropometric indicators of nonalcoholic fatty liver disease patients in intervention groups
Characteristic Symbiotic (n=15) Vitamin E (n=15) Symbiotic + Vitamin E (n=15) Control (n=15) P
Height (cm)
Week 0 172.66±10.97* 171.73±6.48 168.6±9.33 172.93±8.27 0.529†
Week 8 ‑ ‑ ‑ ‑ ‑
P ‑ ‑ ‑ ‑
Weight (kg)
Week 0 80.73±9.12 84.86±12.71 79.8±10.05 83.46±10.25 0.535†
Week 8 80.33±9.17 84.66±12.71 79.6±10.15 96.46±7.33 0.519
P§ 0.111 0.384 0.424 0.610
Waist circumference (cm)
Week 0 93.6±6.52 91.73±9.91 94.93±8.33 96.46±7.33 0.438†
Week 8 93.86±6.65 91.63±10.02 94.86±8.15 96.53±7.5 0.427
P value§ 0.342 0.458 0.433 0.610
BMI (kg/m2)
Week 0 27.28±2.21 28.77±4.08 28.05±2.52 27.84±1.96 0.724‡
Week 8 27.14±2.26 28.7±4.06 27.98±2.65 27.8±1.98 0.684
P|| 0.213 0.575 0.959 0.563
*All values are means±SDs; †Obtained from ANOVA; ‡Obtained from Kruskal-Wallis test; §Obtained from paired t-test; ||Obtained from Wilcoxon signed-rank test. BMI = Body 
mass index; SDs = Standard deviations
Table 2: Serum liver enzymes, glycemic profile, and leptin in nonalcoholic fatty liver disease patients before and after 
intervention
Characteristic Symbiotic (n=15) Vitamin E (n=15) Symbiotic + Vitamin E (n=15) Control (n=15) P
ALT (IU/L)
Week 0 38.14±8.72* 35.73±5.83 38.14±7.77 33.88±4.49 0.27†
Week 8 31.59±9.42 32.06±7.39 25.35±7.98 38.05±6.54 0.001†
Mean difference −6.54±7.66|| −3.66±6.81 −12.79±3.65** 4.16±3.43 <0.001†
AST (IU/L)
Week 0 37.95±15.34 30.53±8.01 36.84±7.3 32.04±7.06 0.048‡
Week 8 30.52±13.4 24.6±6.64 25.47±5.99 34.54±6.8 0.004‡
Mean difference −7.43±8.58 −5.93±6.61 −11.36±4.52** 2.5±5.75 <0.001‡
ALP (IU/L)
Week 0 148.63±26.92 158.1±36.23 147.6±14.95 150.85±21.97 0.813‡
Week 8 133.79±20.88 153.53±38.16 120.79±15.35 156.04±22.52 0.003‡
Mean difference −14.84±12.22 −4.56±9.22 −26.8±11.1** 5.19±2.64 <0.001‡
FBS (mg/dL)
Week 0 115.74±9.9 115.66±12.45 114.13±12.33 108±14.53 0.229‡
Week 8 104.76±7.66 113.6±12.09 98.63±7.14 114.9±13.8 <0.001‡
Mean difference −10.97±6.54 −2.06±9.21 −15.5±8.23** 6.9±7.92 <0.001‡
Insulin (µIU/L)
Week 0 2.24±0.88 2.09±0.41 2.5±0.7 2.13±0.46 0.306‡
Week 8 1.8±0.61 2.05±0.4 1.77±0.53 2.56±0.59 0.001‡
Mean difference −0.44±0.34 −0.04±0.12 −0.72±0.26** 0.42±0.4 <0.001‡
HOMA‑IR
Week 0 0.63±0.20 0.58±0.15 0.56±0.16 0.57±0.16 0.843‡
Week 8 0.75±0.46 0.68±0.26 0.63±0.2 0.67±0.28 0.95‡
Mean difference 0.12±0.37 0.09±0.19 0.07±0.16 0.10±0.21 0.857‡
Leptin (ng/mL)
Week 0 31.18±6.07 29.22±5.3 37.34±3.88 35.75±6.99 0.002‡
Week 8 29.03±4.83 28.74±4.98 25.93±4.56 38.29±6.26 <0.001‡
Mean difference −2.15±3.98 −0.48±2.76 −11.4±2.76** 2.54±3.02 <0.001‡
*All values are means±SDs, †Obtained from ANOVA, ‡Obtained from Kruskal-Wallis test; ||Mean difference reflects week 8 minus week 0 values, **More significant reduction in 
symbiotic + Vitamin E group versus control (P<0.05). ANOVA = Analysis of variance; ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; ALP = Alkaline phosphatase; 
FBS = Fasting blood sugar; HOMA-IR = Homeostasis model assessment for insulin resistance; SDs = Standard deviations
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between and within of each group after the intervention 
[Table 3].
At the end of the 8 weeks treatment period, apo A‑1 
significantly increased in group Sym (P = 0.005) and 
Sym + Vitamin E (P = 0.012). Mean changes of apo A‑1 
from baseline were more significant for Sym group. On 
the other hand, significant reduction in apo B‑100 and 
apo B‑100 to apo A‑1 ratio (apo B100/A‑1 ratio) was 
observed in Sym and Vitamin E group (P ≤ 0.001) after the 
intervention compared to baseline. The reduction in apo 
B100/A‑1 was only significant in Sym group compared 
with control (−0.12 ± 0.07 vs. −0.01 ± 0.07 mg/dL, 
P = 0.003).
Fasting blood sugar, insulin, and homeostasis model 
assessment for insulin resistance
As shown in Table 2, fasting blood sugar (FBS) and serum 
insulin concentrations decreased significantly in Sym and 
Sym + Vitamin E groups after intervention (P = 0.001). 
The reductions in FBS and insulin levels of the 
Sym + Vitamin E group compared with the control were as 
follows: FBS decreased as much as − 15.5 ± 8.23 compared 
with 6.9 ± 7.92 mg/dL (P < 0.001) and insulin − 0.72 ± 0.26 
compared with 0.42 ± 0.4 µIU/mL (P < 0.001). These 
reductions were significant between four groups after 
8‑week of intervention (P < 0.001) [Table 2].
In contrast, when comparing all treatment groups, there was 
no significant difference between four groups on HOMA‑IR 
in our study [Table 2].
Assessment of energy intake and physical activity
No significant differences were observed in reported dietary 
energy intake measured in calories, nutrients, and vitamins 
intake between and/or within the four groups at baseline 
and at the end of the study. In addition, physical activity 
was unchanged throughout the study.
No adverse effects were reported with our symbiotic 
mixture and/or Vitamin E supplement consumption versus 
placebo treatment.
Table 3: Serum lipid profiles in nonalcoholic fatty liver disease patients before and after intervention
Characteristic Symbiotic (n=15) Vitamin E (n=15) Symbiotic + Vitamin E (n=15) Control (n=15) P
Triglycerides (mg/dL)
Week 0 187±46±20.55* 190.6±26.47 186±19.09 182.8±30.2 0.852†
Week 8 167.97±20.24 188.34±24.3 162.56±18.83 186.81±26.94 0.004†
Mean difference −19.49±10.44|| −2.26±6.74 −23.43±5.95** 4.01±36.97 0.001†
Total cholesterol (mg/dL)
Week 0 194.33±24.23 193.2±23.28 185.93±21.44 194.43±15.88 0.658†
Week 8 176.8±18.89 190.13±26.16 167.3±18.79 197.26±15.32 0.001†
Mean difference −17.53±8.91 −3.06±11.15 −18.63±10.64** 2.83±4.19 <0.001†
HDL‑C (mg/dL)
Week 0 46.13±30.27 43.43±10.48 41.32±13.67 38.21±8.31 0.512‡
Week 8 48.33±28.66 45.6±7.78 43.95±9.42 38.52±8.17 0.17‡
Mean difference 2.2±7.05 2.16±9.85 2.63±10.44 0.3±7.14 0.461‡
LDL‑C (mg/dL)
Week 0 139.99±40.5 134.96±10.66 140.86±11.63 138.33±15.06 0.901†
Week 8 124.11±37.32 131.5±10.22 118.86±15.54 139.76±14.78 0.06†
Mean difference −15.88±8.71 −3.46±3.5 −22±10.63** 1.43±2.67 <0.001†
Apo A‑1 (mg/dL)
Week 0 123.93±20.72 128.4±21.53 121.06±17.69 125.53±18.53 0.78†
Week 8 130.4±19.37 133.13±16.2 127.33±16.08 120.06±17.93 0.209†
Mean difference 6.46±7.48†† 4.73±9.6 6.26±8.37 −5.46±5.16 <0.001†
Apo B‑100 (mg/dL)
Week 0 91.86±9.85 87.6±11.03 87.86±18.21 89.53±9.61 0.78†
Week 8 81.46±12.92 81.6±10.06 85.73±18.2 84.26±7.23 0.75†
Mean difference −10.4±7.56 −6±3.76 −2.13±19.73 −5.26±7.17 0.264†
Apo B‑100/A‑1
Week 0 0.75±0.12 0.69±0.11 0.73±0.16 0.72±0.09 0.655†
Week 8 0.63±0.13 0.61±0.09 0.67±0.14 0.71±0.08 0.123†
Mean difference −0.12±0.07†† −0.07±0.05 −0.05±0.16 −0.01±0.07 0.045†
*All values are means±SDs; †Obtained from ANOVA, ‡Obtained from Kruskal-Wallis test; ||Mean difference reflects week 8 minus week 0 values, **More significant reduction in 
symbiotic + Vitamin E group versus control (P<0.05), ††More significant reduction in symbiotic group versus control (P<0.05). ANOVA = Analysis of variance; HDL‑C = High‑density 
lipoprotein cholesterol; LDL‑C = Low‑density lipoprotein cholesterol; Apo A‑1 = Apolipoprotein A‑1; Apo B‑100 = Apolipoprotein B‑100; Apo B‑100/A‑1 = Apolipoprotein B‑100/A‑1; 
SDs = Standard deviations
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DISCUSSION
In the present randomized controlled clinical trial, it was 
shown for the first time that a daily supplementation with 
symbiotic plus Vitamin E for 8 weeks was the most effective 
treatment in lowering levels of serum liver enzymes, some 
markers of lipid profile, serum leptin, FBS concentrations, 
and insulin in NAFLD patients. The findings in this survey 
are the confirmation of the recent studies.
The intestinal mucosa as a defense barrier prevents the 
penetration and the systemic spread of bacteria and 
endotoxins, most of which are lipopolysaccharides (LPS). 
However, failing in this barrier under certain conditions 
leads to bacterial and endotoxin invasion into the GI tract, 
systemic organs, and tissues. These microbial products 
exert proinflammatory actions.[19] Baldwin showed that 
activation of TLR4 by LPS has a distinct effect in promoting 
inflammation and injury in conditions such as alcoholic liver 
disease and NASH.[20] On the other hand, small bacterial 
overgrowth (SIBO) which is present in 50% of patients with 
nonalcoholic steatosis results in tight junction disruption 
and increased gut permeability, which may impact on 
NAFLD progression.[21]
The first question in this study was meant to determine 
the synergistic effect of symbiotic and Vitamin E 
supplementation on changes of liver enzyme levels. NAFLD 
as the most common cause of chronic liver disease is often 
identified by asymptomatic elevation of liver enzymes, 
especially serum ALT levels.[22] In the present study, joint 
symbiotic‑Vitamin E supplementation for 8 weeks led to 
significant reduction in serum ALT, AST, and ALP levels. 
In accordance with our result, Eslamparast et al. in a 
randomized, double‑blind study in NAFLD patients found 
that supplementation with symbiotic, in addition to lifestyle 
modification for 28 weeks, can decrease serum ALT and 
AST levels.[23] In a study by Aller et al., significant reduction 
in serum ALT and AST levels was observed following 
L. bulgaricus and S. thermophilus supplementation in NAFLD 
patients.[14] Similarly, VSL#3 supplementation in NAFLD 
patients significantly decreased these variables.[9] In line with 
these findings, symbiotic plus Vitamin E supplementation 
had more significant reduction in ALT, AST, and ALP 
levels in our study. Collectively, symbiotics exert their 
beneficial effects on liver functions and enzymes through 
manipulation of enteric flora, enhancing the barrier function 
of epithelial cells, decreasing intestinal permeability, and 
endotoxemia in patients with liver diseases.[24]
To the best of our knowledge, only a few studies assessed 
the efficacy of Vitamin E in NAFLD adult patients. In the 
PIVENS trial, 247 nondiabetic and noncirrhotic adults 
with NASH received Vitamin E (800 IU/day), pioglitazone 
(30 mg/day), or placebo for 96 weeks. Compared with 
the placebo, Vitamin E led to a robust improvement in 
NASH.[25] Furthermore, in one meta‑analysis, Sato et al. 
showed beneficial effects of Vitamin E supplementation 
on liver function and histologic changes in patients with 
NAFLD/NASH.[26]
Increased hepatic uptake and synthesis of FFAs led 
to increasing generation of reactive oxygen species 
(ROS).[27] ROS overproduction enhances lipid peroxidation 
and some cytokines production, such as tumor necrosis 
factor‑alpha (TNF‑α) and transforming growth factor‑β 
(TGF‑β).[28] Lipid peroxidation and cytokine production 
generate more ROS production which have deleterious 
effects on HSCs. On the other hand, animal studies 
have shown that Vitamin E as a fat‑soluble vitamin can 
decrease liver enzymes, diminish histological steatosis, and 
necroinflammation. Interestingly, Vitamin E downregulates 
the expression of TGF‑β1, a cytokine implicated in the 
development of liver fibrosis.[29]
We also studied the effects of Vitamin E supplementation in 
combination with symbiotic on serum leptin levels.  Leptin 
levels increase along with increasing fat mass as a 
compensatory mechanism, that limits the expansion of fat 
mass, and preserve insulin sensitivity. Expansion of adipose 
tissue as a result of obesity leads to detrimental effects of 
leptin, by acting as proinflammatory and profibrogenic 
adipokine.[30] Under some conditions, activated HSCs may 
produce leptin in vivo and express LepRb, which activation 
leads to increased expression of proinflammatory and 
proangiogenic cytokines and growth factors so triggering or 
augmenting fibrogenesis.[31] Besides, fatty acids and high‑fat 
feeding can, even in the absence of obesity or systemic IR, 
induce TLRs that in turn trigger inflammation.[32] Some 
studies reported higher leptin levels in NAFLD patients[33] 
while others reported similar levels in NAFLD and controls.[34]
To the best of our knowledge, in literature, no study 
investigated the effect of symbiotic and/or Vitamin E 
supplementation on circulating leptin levels in NAFLD 
patients. Our results showed that combination of symbiotic 
and Vitamin E supplementation reduced leptin levels 
significantly. However, in just one study in NAFLD patients, 
ursodeoxycholic acid with or without Vitamin E did not 
affect leptin levels or BMI, despite an improvement in 
hepatic steatosis.[35] The mechanism by which symbiotics 
act is through suppressing TLR‑related responses by 
altering the intestinal flora,[36] reducing inflammation, and 
improving the liver in animals and humans with fatty 
livers.[9] On the other hand, the exact mechanisms by which 
Vitamin E supplementation might affect leptin levels are 
unknown. Vitamin E as an antioxidant may have favorable 
effects against leptin action on Kupffer cells.[37]
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Abnormalities in lipid and lipoprotein metabolism along 
with chronic inflammation as a result of endotoxemia are 
considered to be the central pathway for the development 
of several obesity‑related comorbidities such as NAFLD and 
CVD.[38] Moreover, the inability of the liver to regulate the 
changes in lipogenesis accompanied by insulin and glucose 
role in adipogenesis are major causes of fat accumulation 
in NAFLD patients.[39] In our study, symbiotic and Vitamin 
E supplementation simultaneously decreased TC, TG, and 
LDL‑C levels significantly, but the results of this study did 
not show any significant increase in HDL‑C levels after 
intervention. Furthermore, apo B100/A‑1, which has a 
strong relationship with NAFLD, significantly decreased 
more in symbiotic group. To our knowledge, up to now, 
no study has examined the effects of symbiotic plus 
Vitamin E on lipid profile in NAFLD patients. Besides, among 
studies that assessed the effects of probiotic or symbiotic 
supplementation, none of them mentioned the lipid profile 
in NAFLD patients.[9,23] Meanwhile, no study investigated the 
positive effects of Vitamin E supplementation on lipid profile 
in these patients.[25] Lipid‑lowering properties of symbiotic 
might be explained by other studies that were conducted in 
diabetic and obese patients. In these studies, VSL#3 along 
with prebiotic supplementation induced changes in the 
microbiota that was associated with an increase in the levels 
of short‑chain fatty acids. Furthermore, probiotic bacteria 
can remove or assimilate cholesterol and can hydrolyze 
conjugated bile  acids, and so excrete them faster.[40]
IR, the physiopathological key to metabolic syndrome and 
to its clinically related diseases, is independently associated 
with NAFLD and its severity;[3,4] however, no study has 
investigated the effects of symbiotic in combination with 
Vitamin E supplementation on IR. The results of our 
study showed a significant reduction in FBS and insulin 
concentrations but not HOMA‑IR. These results agree with 
the findings of Eslamparast et al. that found a significant 
reduction in FBS and serum insulin levels following 
symbiotic supplementation.[23] The present findings seem 
to be consistent with another research which found a 
significant reduction in serum FBS and serum insulin levels 
after treatment with B. Longum and fructooligosaccharide.[10]
In a study by Yakaryilmaz et al., nine patients with 
biopsy‑proven NASH were given oral Vitamin E (800 mg) 
daily for 24 weeks. At the end of the 6 months, fasting insulin 
improved, but serum TC, TG, and FBS levels remained 
unchanged.[41] 800 IU Vitamin E supplementation in another 
study had no effect on IR. The possible reasons for this 
discrepancy might be explained by high dose of Vitamin E 
supplementation and duration of interventions.
Circulating LPS are present at higher concentrations in 
the blood of patients with type 2 diabetes mellitus or IR 
and correlate with insulin, glucose concentrations, and 
HOMA‑IR.[42]   Increase insulin hypersecretion along with 
SIBO and increased intestinal permeability; accelerate liver 
fat accumulation, which lead to NAFLD. Furthermore, gut 
microbiota has been shown to affect fat storage and energy 
harvesting, playing an important role in the development of 
IR.[43] The mechanisms by which symbiotics could improve 
IR and lipid profile are thought to be by modulation of the 
intestinal microflora composition, reduction of endotoxemia, 
increases in fecal pH, suppression of inflammation and 
reduction in the production and absorption of intestinal 
toxins.[44] It was well established that Vitamin E reducing 
IR mechanisms are through suppressing oxidative stress 
and peroxisome proliferator‑activated receptor‑alpha 
expression.[41]
The strengths of our study include its randomized, double‑blind, 
placebo‑controlled design, combination of symbiotic and 
Vitamin E supplementation, and the strong compliance and 
retention of patients to the experimental program.
The main limitation of this survey is its relatively small 
sample size and the measurement time which reduced our 
power to detect differences among subgroups. In addition, 
in our study, we had to convince the participants to be 
merely strict on consuming not probiotic products during 
the study although we could unravel the problem by regular 
weekly phone calls.
Another limitation of this study is that the diagnosis of liver 
disease was not confirmed by liver biopsy as it is difficult 
to perform due to ethical reasons; hence, further studies, 
which take these variables into account, will need to be 
undertaken. Compelling of evidence has indicated that 
bacterial count and using fecal sample provide a better 
estimate of intervention with probiotics. In subsequent 
study, we will make every effort to collect fecal samples 
to evaluate changes in bacterial species and abundance in 
particular, among NAFLD patients.
CONCLUSION
Significant findings emerged from this study are that 400 IU 
Vitamin E in combination with symbiotic supplements can 
decrease the liver enzymes, serum insulin, FBS, and leptin 
levels along with some lipid profiles in NAFLD patients.
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